GCM
ITCI

Graham Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Graham Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,791
Closed -$500K – 1697
2025
Q1 		$500K Buy
3,791
+591
+18% +$73.7K 0.01% 808
2024
Q4 		$267K Sell
3,200
-737
-19% -$60.6K ﹤0.01% 974
2024
Q3 		$288K Sell
3,937
-616
-14% -$46.3K 0.01% 793
2024
Q2 		$312K Sell
4,553
-12,554
-73% -$871K 0.01% 720
2024
Q1 		$1.18M Buy
+17,107
New +$1.18M 0.02% 379
2023
Q1 		– Sell
-15,339
Closed -$812K – 1374
2022
Q4 		$812K Buy
+15,339
New +$769K 0.02% 618

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Graham Capital Management's ITCI Position: Q2 2025 in Review

Graham Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 3,791 shares — an estimated $500K sold.

Graham Capital Management first reported a position in ITCI in Q4 2022 and held it in 6 quarters. The position peaked at $1.18M in Q1 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Graham Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Graham Capital Management sold 3,791 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $500K.
  • Graham Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2022 and held it in 6 quarters.
  • Graham Capital Management's Intra-Cellular Therapies Inc. position peaked at $1.18M in Q1 2024.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Graham Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.